Aurobindo Pharma in talks to buy API units of Actavis in Western Europe

Aurobindo Pharma is in talks with global pharma giant Actavis to buy their API units in Western Europe, sources familiar with the development suggest. This is in-line with Aurobindo’s strategy to vertically integrate their injectables business by buying ingredient making units.

Actavis wants to sell loss making units in IItaly, Spain, France, Germany and the Netherlands. The API units have a revenue of close to $500 mn. Aurobindo Pharma is said to be in talks to buy one or two units.

Aurobindo Pharma has been boosting it’s API portfolio, had recently acquired Andhra Pradesh- based Hyacinths Pharma.

Aurobindo Pharma’s spokesperson declined to comment on the development. Actavis’ spokesperson said, “As a matter of corporate policy we do not comment on rumors or speculation regarding business development activities, so we have no comment here.”